Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

被引：10
|
作者：
Yuan, Zhongyu
Huang, Jia-Jia
Hua, Xin
Zhao, Jian-Li
Lin, Ying
Zhang, Yuan-Qi
Wu, Zhiyong
Zhang, Lehong
Bi, Xiwen
Xia, Wen
Zhong, Yong-Yi
Wang, Shu-Sen
Xu, Fei
Hong, Ruoxi
Jiang, Kuikui
Shi, Yanxia
Xue, Cong
An, Xin
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[4] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Oncol, Guangzhou, Peoples R China
[8] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[9] Shantou Cent Hosp, Dept Breast Surg, Shantou, Peoples R China
[10] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Peoples R China
[11] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[12] Sun Yat Sen Univ, Ctr Canc, Dept Med, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
[13] Sun Yat Sen Univ, Ctr Canc, Dept Oncol, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
    Yuan, Yang
    Zhang, Shaohua
    Yan, Min
    Yin, Yongmei
    Song, Yuhua
    Jiang, Zefei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (10)
  • [22] Hormone therapy versus chemotherapy as first-line treatment for estrogen receptor-positive metastatic breast cancer (MBC) patients
    Chang, T. Y.
    Lin, C.
    Lu, Y.
    Kuo, S. H.
    Huang, S.
    Huang, C.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer
    Sakaguchi, K.
    Nakatsukasa, K.
    Taguchi, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 99 - 99
  • [24] Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
    Sakaguchi, Koichi
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Kato, Makoto
    Sakuyama, Akira
    Matsuda, Takayuki
    Tsunoda, Nobuyuki
    Fujiwara, Ikuya
    Yamaguchi, Masahide
    Tanaka, Hiroki
    Onishi, Kazuyoshi
    Onishi, Mie
    Yoshino, Yuji
    Kikuchi, Takashi
    Taguchi, Tetsuya
    ANTICANCER RESEARCH, 2018, 38 (07) : 4073 - 4081
  • [25] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    CANCER RESEARCH, 2013, 73
  • [26] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    Crown, J.
    Kennedy, M. J.
    Tresca, P.
    Marty, M.
    Espie, M.
    Burris, H. A.
    DeSilvio, M.
    Lau, M. R.
    Kothari, D.
    Koch, K. M.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
  • [27] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply
    Ellis, Matthew J.
    Robertson, John F. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1960 - +
  • [28] Lapatinib In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Curran, Monique P.
    DRUGS, 2010, 70 (11) : 1411 - 1422
  • [29] Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer
    Kinikoglu, Oguzcan
    Odabas, Hatice
    Altintas, Yunus Emre
    Yildiz, Anil
    Cakan, Burcin
    Akdag, Goncaguel
    Yildirim, Sedat
    Bal, Hamit
    Kaya, Tugba
    Tunbekici, Salih
    Isik, Deniz
    Basoglu, Tugba
    Yildirim, Mahmut Emre
    Turan, Nedim
    MEDICINA-LITHUANIA, 2024, 60 (06):
  • [30] Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN)
    Rimawi, Mothaffar F.
    Poole, Christopher John
    Ferrero, Jean-Marc
    Rodriguez, Juan R. De la Haba
    Mitchell, Lada
    Pelizon, Christina H.
    Arpino, Grazia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345